We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen, Inc. (INGN - Free Report) , is a medical technology company. Inogen outperformed its industry in a year’s time. Solid domestic and international business-to-business sales are the primary reason behind the stock's solid performance. Buoyed by positive second-quarter results, the company raised its 2018 revenue guidance fairly significantly, representing solid, double digit, year-over-year growth. Inogen’s expanding product portfolio is a key catalyst. See why this is a unique Med-Tech story.
Tesla Inc. (TSLA - Free Report) , designs, develops, manufactures, and sells electric vehicles and stationary energy storage products. In third-quarter 2018, Tesla’s earnings per share and revenues surpassed the Zacks Consensus Estimates. Also, both earnings and revenues improved year over year. Over the past six months, shares of Tesla outperformed the industry it belongs to. Moreover, over the past month, the Zacks Consensus Estimates for both the current quarter and current year earnings moved upwards. Also, the company is actively undertaking mergers and acquisitions to meet its targets and expand its business.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Top Stock Picks for the Week of November 5th
Inogen, Inc. (INGN - Free Report) , is a medical technology company. Inogen outperformed its industry in a year’s time. Solid domestic and international business-to-business sales are the primary reason behind the stock's solid performance. Buoyed by positive second-quarter results, the company raised its 2018 revenue guidance fairly significantly, representing solid, double digit, year-over-year growth. Inogen’s expanding product portfolio is a key catalyst. See why this is a unique Med-Tech story.
Tesla Inc. (TSLA - Free Report) , designs, develops, manufactures, and sells electric vehicles and stationary energy storage products. In third-quarter 2018, Tesla’s earnings per share and revenues surpassed the Zacks Consensus Estimates. Also, both earnings and revenues improved year over year. Over the past six months, shares of Tesla outperformed the industry it belongs to. Moreover, over the past month, the Zacks Consensus Estimates for both the current quarter and current year earnings moved upwards. Also, the company is actively undertaking mergers and acquisitions to meet its targets and expand its business.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>